Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

7.7%

1 terminated/withdrawn out of 13 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

60%

3 of 5 completed trials have results

Key Signals

4 recruiting3 with results

Enrollment Performance

Analytics

Phase 2
11(84.6%)
Early Phase 1
1(7.7%)
Phase 1
1(7.7%)
13Total
Phase 2(11)
Early Phase 1(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (13)

Showing 13 of 13 trials
NCT07223424Phase 2Recruiting

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

Role: lead

NCT05130177Phase 2Active Not Recruiting

Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma

Role: lead

NCT05669846Phase 2Recruiting

Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC

Role: lead

NCT06070012Phase 2Recruiting

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

Role: lead

NCT06499896Phase 2Recruiting

Healthy-donor Microbiome MTP-101-C in Steroid Relapse/Refractory Immune-related Cutaneous Adverse Events (irCAEs) and Immune-mediated Colitis (IMC)

Role: lead

NCT04139902Phase 2Active Not Recruiting

Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma

Role: lead

NCT06030037Phase 2Withdrawn

Pembrolizumab/Lenvatinib With and Without Healthy Donor FMT (hdFMT) in Relapsed/ Refractory (R/R) Melanoma

Role: lead

NCT04808999Phase 2Active Not Recruiting

Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC)

Role: lead

NCT03618641Phase 2Completed

CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease

Role: lead

NCT05061017Phase 2Completed

Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)

Role: lead

NCT04401995Phase 2Completed

Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination with Nivolumab Vs. Nivolumab

Role: lead

NCT01608594Phase 1Completed

Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for Melanoma

Role: lead

NCT00972933Early Phase 1Completed

Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma

Role: lead

All 13 trials loaded